Literature DB >> 30667332

Emerging Applications of Artificial Intelligence in Neuro-Oncology.

Jeffrey D Rudie1, Andreas M Rauschecker1, R Nick Bryan1, Christos Davatzikos1, Suyash Mohan1.   

Abstract

Due to the exponential growth of computational algorithms, artificial intelligence (AI) methods are poised to improve the precision of diagnostic and therapeutic methods in medicine. The field of radiomics in neuro-oncology has been and will likely continue to be at the forefront of this revolution. A variety of AI methods applied to conventional and advanced neuro-oncology MRI data can already delineate infiltrating margins of diffuse gliomas, differentiate pseudoprogression from true progression, and predict recurrence and survival better than methods used in daily clinical practice. Radiogenomics will also advance our understanding of cancer biology, allowing noninvasive sampling of the molecular environment with high spatial resolution and providing a systems-level understanding of underlying heterogeneous cellular and molecular processes. By providing in vivo markers of spatial and molecular heterogeneity, these AI-based radiomic and radiogenomic tools have the potential to stratify patients into more precise initial diagnostic and therapeutic pathways and enable better dynamic treatment monitoring in this era of personalized medicine. Although substantial challenges remain, radiologic practice is set to change considerably as AI technology is further developed and validated for clinical use. © RSNA, 2019.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30667332      PMCID: PMC6389268          DOI: 10.1148/radiol.2018181928

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  102 in total

1.  Prediction of pseudoprogression in patients with glioblastomas using the initial and final area under the curves ratio derived from dynamic contrast-enhanced T1-weighted perfusion MR imaging.

Authors:  C H Suh; H S Kim; Y J Choi; N Kim; S J Kim
Journal:  AJNR Am J Neuroradiol       Date:  2013-07-04       Impact factor: 3.825

2.  Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging.

Authors:  Hee Ho Chu; Seung Hong Choi; Inseon Ryoo; Soo Chin Kim; Jeong A Yeom; Hwaseon Shin; Seung Chai Jung; A Leum Lee; Tae Jin Yoon; Tae Min Kim; Se-Hoon Lee; Chul-Kee Park; Ji-Hoon Kim; Chul-Ho Sohn; Sung-Hye Park; Il Han Kim
Journal:  Radiology       Date:  2013-10-28       Impact factor: 11.105

3.  Differentiation of tumor progression from pseudoprogression in patients with posttreatment glioblastoma using multiparametric histogram analysis.

Authors:  J Cha; S T Kim; H-J Kim; B-J Kim; Y K Kim; J Y Lee; P Jeon; K H Kim; D-S Kong; D-H Nam
Journal:  AJNR Am J Neuroradiol       Date:  2014-03-27       Impact factor: 3.825

4.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.

Authors:  Roel G W Verhaak; Katherine A Hoadley; Elizabeth Purdom; Victoria Wang; Yuan Qi; Matthew D Wilkerson; C Ryan Miller; Li Ding; Todd Golub; Jill P Mesirov; Gabriele Alexe; Michael Lawrence; Michael O'Kelly; Pablo Tamayo; Barbara A Weir; Stacey Gabriel; Wendy Winckler; Supriya Gupta; Lakshmi Jakkula; Heidi S Feiler; J Graeme Hodgson; C David James; Jann N Sarkaria; Cameron Brennan; Ari Kahn; Paul T Spellman; Richard K Wilson; Terence P Speed; Joe W Gray; Matthew Meyerson; Gad Getz; Charles M Perou; D Neil Hayes
Journal:  Cancer Cell       Date:  2010-01-19       Impact factor: 31.743

5.  Addition of MR imaging features and genetic biomarkers strengthens glioblastoma survival prediction in TCGA patients.

Authors:  Manal Nicolasjilwan; Ying Hu; Chunhua Yan; Daoud Meerzaman; Chad A Holder; David Gutman; Rajan Jain; Rivka Colen; Daniel L Rubin; Pascal O Zinn; Scott N Hwang; Prashant Raghavan; Dima A Hammoud; Lisa M Scarpace; Tom Mikkelsen; James Chen; Olivier Gevaert; Kenneth Buetow; John Freymann; Justin Kirby; Adam E Flanders; Max Wintermark
Journal:  J Neuroradiol       Date:  2014-07-02       Impact factor: 3.447

6.  Automatic detection and segmentation of brain metastases on multimodal MR images with a deep convolutional neural network.

Authors:  Odelin Charron; Alex Lallement; Delphine Jarnet; Vincent Noblet; Jean-Baptiste Clavier; Philippe Meyer
Journal:  Comput Biol Med       Date:  2018-02-09       Impact factor: 4.589

7.  Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials.

Authors:  W J Curran; C B Scott; J Horton; J S Nelson; A S Weinstein; A J Fischbach; C H Chang; M Rotman; S O Asbell; R E Krisch
Journal:  J Natl Cancer Inst       Date:  1993-05-05       Impact factor: 13.506

Review 8.  Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials.

Authors:  Benjamin M Ellingson; Patrick Y Wen; Timothy F Cloughesy
Journal:  Neurotherapeutics       Date:  2017-04       Impact factor: 7.620

9.  Imaging-genomics reveals driving pathways of MRI derived volumetric tumor phenotype features in Glioblastoma.

Authors:  Patrick Grossmann; David A Gutman; William D Dunn; Chad A Holder; Hugo J W L Aerts
Journal:  BMC Cancer       Date:  2016-08-08       Impact factor: 4.430

10.  Non-invasive detection of 2-hydroxyglutarate in IDH-mutated gliomas using two-dimensional localized correlation spectroscopy (2D L-COSY) at 7 Tesla.

Authors:  Gaurav Verma; Suyash Mohan; MacLean P Nasrallah; Steven Brem; John Y K Lee; Sanjeev Chawla; Sumei Wang; Rajakumar Nagarajan; M Albert Thomas; Harish Poptani
Journal:  J Transl Med       Date:  2016-09-22       Impact factor: 5.531

View more
  47 in total

1.  Sexually dimorphic radiogenomic models identify distinct imaging and biological pathways that are prognostic of overall survival in glioblastoma.

Authors:  Niha Beig; Salendra Singh; Kaustav Bera; Prateek Prasanna; Gagandeep Singh; Jonathan Chen; Anas Saeed Bamashmos; Addison Barnett; Kyle Hunter; Volodymyr Statsevych; Virginia B Hill; Vinay Varadan; Anant Madabhushi; Manmeet S Ahluwalia; Pallavi Tiwari
Journal:  Neuro Oncol       Date:  2021-02-25       Impact factor: 12.300

Review 2.  Neuro-Oncology and Radiogenomics: Time to Integrate?

Authors:  A Lasocki; M A Rosenthal; S J Roberts-Thomson; A Neal; K J Drummond
Journal:  AJNR Am J Neuroradiol       Date:  2020-09-10       Impact factor: 3.825

Review 3.  Machine learning approaches to study glioblastoma: A review of the last decade of applications.

Authors:  Jessica Valdebenito; Felipe Medina
Journal:  Cancer Rep (Hoboken)       Date:  2019-12

Review 4.  Can artificial intelligence overtake human intelligence on the bumpy road towards glioma therapy?

Authors:  Precilla S Daisy; T S Anitha
Journal:  Med Oncol       Date:  2021-04-03       Impact factor: 3.064

5.  Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: response, progression, and pseudoprogression.

Authors:  Norbert Galldiks; Martin Kocher; Garry Ceccon; Jan-Michael Werner; Anna Brunn; Martina Deckert; Whitney B Pope; Riccardo Soffietti; Emilie Le Rhun; Michael Weller; Jörg C Tonn; Gereon R Fink; Karl-Josef Langen
Journal:  Neuro Oncol       Date:  2020-01-11       Impact factor: 12.300

Review 6.  Emerging MRI Techniques to Redefine Treatment Response in Patients With Glioblastoma.

Authors:  Fabrício Guimarães Gonçalves; Sanjeev Chawla; Suyash Mohan
Journal:  J Magn Reson Imaging       Date:  2020-03-19       Impact factor: 4.813

7.  Adding DSC PWI and DWI to BT-RADS can help identify postoperative recurrence in patients with high-grade gliomas.

Authors:  Yuelong Yang; Yunjun Yang; Xiaoling Wu; Yi Pan; Dong Zhou; Hongdan Zhang; Yonglu Chen; Jiayun Zhao; Zihua Mo; Biao Huang
Journal:  J Neurooncol       Date:  2020-01-04       Impact factor: 4.130

8.  Deep learning-based detection and segmentation-assisted management of brain metastases.

Authors:  Jie Xue; Bao Wang; Yang Ming; Xuejun Liu; Zekun Jiang; Chengwei Wang; Xiyu Liu; Ligang Chen; Jianhua Qu; Shangchen Xu; Xuqun Tang; Ying Mao; Yingchao Liu; Dengwang Li
Journal:  Neuro Oncol       Date:  2020-04-15       Impact factor: 12.300

Review 9.  MRI biomarkers in neuro-oncology.

Authors:  Marion Smits
Journal:  Nat Rev Neurol       Date:  2021-06-20       Impact factor: 42.937

10.  Three-dimensional U-Net Convolutional Neural Network for Detection and Segmentation of Intracranial Metastases.

Authors:  Jeffrey D Rudie; David A Weiss; John B Colby; Andreas M Rauschecker; Benjamin Laguna; Steve Braunstein; Leo P Sugrue; Christopher P Hess; Javier E Villanueva-Meyer
Journal:  Radiol Artif Intell       Date:  2021-03-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.